Quest Diagnostics
About: Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Employees: 56,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
103% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 59
81% more call options, than puts
Call options by funds: $63.1M | Put options by funds: $35M
5% more funds holding
Funds holding: 832 [Q3] → 874 (+42) [Q4]
2.31% more ownership
Funds ownership: 86.15% [Q3] → 88.46% (+2.31%) [Q4]
5% more repeat investments, than reductions
Existing positions increased: 306 | Existing positions reduced: 292
0% more capital invested
Capital invested by funds: $14.9B [Q3] → $14.9B (+$23.3M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$180
4%
upside
Avg. target
$190
10%
upside
High target
$200
16%
upside
9 analyst ratings
3 positive
33%
6 neutral
67%
0 negative
0%
JP Morgan Lisa Gill 100% 1-year accuracy 4 / 4 met price target | 10%upside $190 | Neutral Maintained | 6 May 2025 |
Piper Sandler David Westenberg 48% 1-year accuracy 15 / 31 met price target | 16%upside $200 | Neutral Maintained | 28 Apr 2025 |
Truist Securities David Macdonald 62% 1-year accuracy 64 / 103 met price target | 10%upside $190 | Hold Maintained | 23 Apr 2025 |
Barclays Stephanie Davis 75% 1-year accuracy 9 / 12 met price target | 7%upside $185 | Equal-Weight Maintained | 23 Apr 2025 |
Evercore ISI Group Elizabeth Anderson 100% 1-year accuracy 1 / 1 met price target | 4%upside $180 | In-Line Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 15 articles about DGX published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Should You Continue to Retain DGX Stock in Your Portfolio?
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.
Neutral
PRNewsWire
1 day ago
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet" Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence early enough (50%) are among the primary reasons cancer recurrence is typically missed, according to oncologists whose patients' cancer recurrence was missed in an earlier stage 94% of oncologists say circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing could reduce diagnosis delays in cancer recurrence but cite hurdles to wide adoption SECAUCUS, N.J. , May 13, 2025 /PRNewswire/ -- Oncologists feel they are seeing more and more patients with advanced cancers, say screening barriers are the leading reason why, and worry that current tests may not catch cancer recurrence early enough, according to a new report, "The Cancer Paradox: Oncologists' Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring.
Neutral
Zacks Investment Research
1 week ago
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Positive
Seeking Alpha
1 week ago
Quest Diagnostics: A Leader But Waiting For Better Price
Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to buy DGX at $140 for a 15% IRR, as the current valuation is high. Valuation analysis shows DGX trading at a premium; base case IRR is 8.46%, below my 15% threshold, warranting a Hold rating.
Positive
Benzinga
3 weeks ago
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.
Positive
Benzinga
3 weeks ago
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.
Neutral
Seeking Alpha
3 weeks ago
Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Pito Chickering - Deutsche Bank Noah Kava - Jefferies David Westenberg - Piper Sandler Michael Ryskin - Bank of America Andrew Brackmann - William Blair Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics First Quarter 2025 Conference Call. At the request of the company, this call is being recorded.
Positive
Zacks Investment Research
3 weeks ago
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
DGX delivers solid top-line growth in the first quarter of 2025.
Positive
Investors Business Daily
3 weeks ago
Quest Diagnostics Looks Like A 'Safe Haven' After First-Quarter Beat
Quest Diagnostics stock remains a "safe haven," an analyst said Tuesday after the company topped first-quarter expectations.
Positive
Zacks Investment Research
3 weeks ago
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.
Charts implemented using Lightweight Charts™